Therapeutic proteins are proteins that are engineered in the laboratory for pharmaceutical use, including non-covalent binders, therapeutic proteins such as enzymes and albumin are having properties such as breaking of covalent bongs and therefore has wide application of treatment .Therapeutic proteins are highly effective in vivo and in-vitro treatment of diseases. Oral vaccines are biologically prepared products, which provide active acquired immunity to diseases such as cholera, polio, rotavirus, smallpox, yellow fever, and others. An oral vaccine comprise an agent resembling to the disease causing microorganism. The vaccines are generally developed from live attenuated or killed forms of the disease causing microorganism, its toxins, or its surface proteins.
Figure 1. Global Therapeutic Proteins and Oral Vaccines Market Value (US$ Mn), 2016-2027
The global therapeutic proteins and oral vaccines market size is estimated to be valued at US$ 201,042.7 million in 2020 and is expected to exhibit a CAGR of 6.7% over the forecast period (2020-2027).
The increasing investments by key players for the development of promising therapies for treatment of different disease conditions is expected to drive the market growth over the forecast period. For instance, in March 2020, research scientists at Migal Galilee Research Institute Ltd, the research and development center of MigVax Ltd, announced to develop a oral vaccine for a deadly coronavirus virus affecting poultry could be adapted for human use against the novel coronavirus known as 2019-nCoV and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Moreover, increasing prevalence of oncology disease is expected to drive growth of the global therapeutic proteins and oral vaccines market. For instance, according to the World Health Organization report published in September 2018, cancer is the second leading cause of death globally, with around 70% of deaths occurring in low and middle income countries.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2020: | US$ 201,042.7 Mn |
| Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: | 6.7% | 2027 Value Projection: | US$ 316,684.7 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Abbott Laboratories, Amgen, Inc., Biogen, Inc, Eily, Lilly, and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc. , TransAlgae, MigVax Ltd, and Lumen Bioscience, Inc |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Global Therapeutic Proteins and Oral Vaccines Market- Impact of Coronavirus (Covid-19) Pandemic
The increasing prevalence of COVID-19 has caused production factories to shutdown in almost all sectors, and also affected the supply of raw materials and Active Pharmaceutical Ingredients (API) of the manufacturing companies across the globe. Moreover, various guidelines have been implemented by regulatory authorities for manufacturing of active pharmaceutical ingredients and pharmaceutical products to avoid the spread of COVID-19 and also to reduce the contamination of active pharmaceutical ingredients during the manufacturing process of pharmaceuticals products such as vaccines, tablets, and others.
According to the U.S. Food Drug and Administration’s report of June 2020, owing to the COVID-19 public health emergency, drug manufacturers are required to abide by the following current good manufacturing practice (CGMP) regulations and recommendations regarding restriction of sick employees from production areas. 1) Any employee or worker in a production unit should be medically evaluated for infectious diseases such as COVID-19. 2) If any of individual is exhibiting COVID-19 symptoms, they shall be restricted from entering the production house premises of the company to prevent contamination of drugs and active pharmaceutical ingredients (API).
Thus, the COVID-19 pandemic has negatively affected the Global therapeutic protein and oral vaccine market.
Figure 2. Global Therapeutic Proteins and Oral Vaccines Market Share (%) by Region, 2020
In North America, increasing prevalence of cardiovascular disorders (CVDs) such as coronary heart failure and others is expected to drive the demand of therapeutic proteins for the treatment of cardiovascular diseases, which in turn is expected to boost growth of the global therapeutic proteins and oral vaccines market over the forecast period. For instance, according to the American Heart Association’s Heart Disease and Stroke Statistics 2018, around 92.1 million adults in the U.S. suffered from some form of CVD or the after-effects of stroke.
Moreover, in Europe, increasing number of conferences and symposiums conducted in Europe, which are focused on spreading knowledge about recent advancements in biopharmaceutical field is expected to create a lucrative environment for the market growth. For instance, in September 2018, 6th European Biopharma Congress was held at Amsterdam, Netherlands. The subject of this conference was novel strategies and advancements in biopharmaceutics. Researchers and scientists participating in this seminar discussed on cell therapy, biotechnology, therapeutic biological products, gene therapy, biosimilars, drug discovery, and clinical trials.
Furthermore, Middle-to-lower income countries such as India, Indonesia, Bangladesh, Mexico, Brazil, and certain European countries do not have proper availability of biologics due to high cost and lack of reimbursement for biologics. Therefore, lower availability and affordability of biologics in middle and lower income countries are expected to hamper the biologics market growth over the forecast period. For instance, according to article 'Affordability Issues of Biotech Drugs in Low- and Middle-Income Countries (LMICs)' published in Drug Designing and Intellectual Properties International Journal 2019, in India alone, as many as 63 million people are forced into poverty every year, owing to very high health expenses, the majority of which are out-of-pocket payments for medicines. These factors are expected to restraint the global therapeutic proteins and oral vaccines market.
Key Players
Major players operating in global therapeutic proteins and oral vaccines market include Abbott Laboratories, Amgen, Inc., Biogen, Inc, Eily, Lilly, and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc., TransAlgae, MigVax Ltd, and Lumen Bioscience, Inc
Oral administration of vaccines is the most convenient way of vaccination, owing to the factors such as oral vaccines are non-invasive, safe, and suitable for all age groups, especially children. Oral vaccines are mostly preferred for mass vaccination and are mostly liquid filled in sachet or blister. Oral vaccines are commonly available for diseases such as typhoid, cholera, adenovirus, rotavirus, and others.
Therapeutic proteins can be used to replace a protein that is abnormal or deficient in a particular disease. They can also augment the body’s supply of a beneficial protein to help reduce the impact of disease or chemotherapy. Genetically engineered proteins can closely resemble the natural proteins they replace, or they can be enhanced by adding sugars or other molecules that extend the protein’s duration of therapeutic activity in patients.
Market Dynamics
Key companies focusing on product approvals of oral vaccines and therapeutic proteins, is expected to drive the global therapeutic proteins and oral vaccines market. For instance, in July 2018, Emergent BioSolutions Inc. announced that it received marketing authorization from European Medicine Agency for its oral typhoid vaccine Vivotif (Typhoid Vaccine Live Oral Ty21a) in five European countries such as France, Portugal, Poland, Czech Republic, and Slovakia. Moreover, in May 2018, Amgen Inc. received the U.S. Food and Drug Administration approval for Aimovig (erenumab-aooe), indicated for preventive treatment of migraine in adults.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients